These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26287490)

  • 21. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China.
    Liu C; Chen ZJ; Sun Z; Feng X; Zou M; Cao W; Wang S; Zeng J; Wang Y; Sun M
    J Microbiol Immunol Infect; 2015 Oct; 48(5):490-6. PubMed ID: 24767415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
    Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
    J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
    Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
    J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan--SMART program, 2003.
    Ho CM; Hsueh PR; Liu CY; Lee SY; Chiueh TS; Shyr JM; Tsao SM; Chuang YC; Yan JJ; Wang LS; Wang JH; Ho MW; Tien N; Lu JJ
    Eur J Clin Microbiol Infect Dis; 2010 Apr; 29(4):383-9. PubMed ID: 20155296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
    Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
    J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital.
    Di Gregorio S; Perazzi B; Ordoñez AM; De Gregorio S; Foccoli M; Lasala MB; García S; Vay C; Famiglietti A; Mollerach M
    Microb Drug Resist; 2015 Feb; 21(1):25-34. PubMed ID: 25535825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
    Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.
    Bae IG; Federspiel JJ; Miró JM; Woods CW; Park L; Rybak MJ; Rude TH; Bradley S; Bukovski S; de la Maria CG; Kanj SS; Korman TM; Marco F; Murdoch DR; Plesiat P; Rodriguez-Creixems M; Reinbott P; Steed L; Tattevin P; Tripodi MF; Newton KL; Corey GR; Fowler VG;
    J Infect Dis; 2009 Nov; 200(9):1355-66. PubMed ID: 19811099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
    Tran N; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
    Fong RK; Low J; Koh TH; Kurup A
    Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):983-7. PubMed ID: 19387707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiomics characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates with heterogeneous intermediate resistance to vancomycin (hVISA) in Latin America.
    Castro BE; Rios R; Carvajal LP; Vargas ML; Cala MP; León L; Hanson B; Dinh AQ; Ortega-Recalde O; Seas C; Munita JM; Arias CA; Rincon S; Reyes J; Diaz L
    J Antimicrob Chemother; 2022 Dec; 78(1):122-132. PubMed ID: 36322484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
    Cafiso V; Bertuccio T; Spina D; Purrello S; Campanile F; Di Pietro C; Purrello M; Stefani S
    PLoS One; 2012; 7(1):e29573. PubMed ID: 22253738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein Biomarker Discovery for Methicillin-Sensitive, Heterogeneous Vancomycin-Intermediate and Vancomycin-Intermediate
    Liu YC; Lu JJ; Lin LC; Lin HC; Chen CJ
    J Proteome Res; 2021 Jan; 20(1):164-171. PubMed ID: 33058664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
    Rybak MJ; Leonard SN; Rossi KL; Cheung CM; Sader HS; Jones RN
    J Clin Microbiol; 2008 Sep; 46(9):2950-4. PubMed ID: 18632899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China.
    Wang Y; Hu YJ; Ai XM; Xu HT; Sun TY
    Chin Med J (Engl); 2013 Feb; 126(3):505-9. PubMed ID: 23422115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ; Lin MH; Shu JC; Lu JJ
    J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.